DosePhi
🔄

Alpha-Lipoic Acid

Antioxidants

Also known as: ALA, Lipoic Acid, Thioctic Acid

Alpha-Lipoic Acid is a unique antioxidant that works in both water and fat environments. It recycles other antioxidants (vitamins C, E, glutathione, CoQ10) and supports blood sugar regulation and nerve health.

Best Timing

Take on an empty stomach 30 minutes before meals for best absorption. R-ALA form is more stable and better absorbed.

Absorption

Absorption is reduced by food. R-ALA is the natural, more bioactive form. Na-R-ALA is stabilized for better shelf life and absorption.

Health Goals
🧬Longevity⚡Energy❤️Heart
Who Should Take This
Elderly (60+)High-Stress Individuals
  • Universal antioxidant (works in water and fat)
  • Recycles vitamins C, E, glutathione, and CoQ10
  • Supports blood sugar regulation and insulin sensitivity
  • Protects nerves and reduces neuropathy symptoms
  • Supports liver detoxification
  • May support healthy aging and mitochondrial function
General antioxidant300–600 mg

Daily

Blood sugar support600–1,200 mg

Daily in divided doses

Neuropathy600 mg

Daily

R-ALA form preferred

R-ALA specifically150–300 mg

Daily

More potent than racemic — lower dose needed

  • -R-Lipoic Acid (R-ALA) – natural form, more bioactive
  • -S-Lipoic Acid – synthetic, less active
  • -Racemic mixture (R/S-ALA) – 50/50, most common
  • -Na-R-ALA (sodium salt) – stabilized R-ALA, better absorption
Red meat (especially organ meats)Spinach and broccoliTomatoesPeas and Brussels sproutsRice bran
CoQ10Synergy

ALA regenerates CoQ10, extending its antioxidant activity.

Vitamin CSynergy

ALA recycles oxidized vitamin C back to its active form.

Vitamin ESynergy

ALA regenerates vitamin E, forming an antioxidant network.

Vitamin B1 (Thiamine)Caution

ALA may increase thiamine requirements. Ensure adequate B1 intake.

IronCaution

ALA chelates metals including iron. Separate by 2+ hours.

Alpha-lipoic acid for diabetic neuropathy

Ziegler D, Low PA, et al. - Diabetes Care (2006)

600 mg ALA IV for 3 weeks significantly improved neuropathic symptoms and deficits in diabetic patients (NATHAN II trial).